Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cantourage Group SEFRA:HIGH 20 Earnings Yield (Joel Greenblatt) % is 0.00% as of Jun. 2025. GuruFocus rates FRA:HIGH with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Cantourage Group SE ranks worse than 66.93% on this metric.
Cantourage Group SE's Enterprise Value for the quarter that ended in Jun. 2025 was €64.79 Mil.
Cantourage Group SE's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 was €0.05 Mil. Cantourage Group SE's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2025 was 0.00%.
The historical rank and industry rank for Cantourage Group SE's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
FRA:HIGH'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -15.52 Med: -6.05 Max: 0.07
Current: 0.07
During the past 5 years, the highest Earnings Yield (Joel Greenblatt) of Cantourage Group SE was 0.07%. The lowest was -15.52%. And the median was -6.05%.
FRA:HIGH's Earnings Yield (Joel Greenblatt) % is ranked worse than 66.93% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 3.25
vs FRA:HIGH: 0.07
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Cantourage Group SE's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Cantourage Group SE (FRA:HIGH) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Cantourage Group SE Earnings Yield (Joel Greenblatt) % Related Terms
Cantourage Group SE Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Cantourage Group SE's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cantourage Group SE Earnings Yield (Joel Greenblatt) % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Cantourage Group SE's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cantourage Group SE Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cantourage Group SE's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Cantourage Group SE's Earnings Yield (Joel Greenblatt) % falls into.
Cantourage Group SE Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Cantourage Group SEs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 0.00% mean?
Cantourage Group SE (FRA:HIGH) has a Earnings Yield (Joel Greenblatt) % of 0.00% as of Jun. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Cantourage Group SE and its competitors. According to the industry distribution chart, Cantourage Group SE ranks #674 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 66.9%.
Is Cantourage Group SE's Earnings Yield (Joel Greenblatt) % too high?
Cantourage Group SE's current Earnings Yield (Joel Greenblatt) % is 0.00%. Based on the distribution chart, Cantourage Group SE ranks #674 out of 1007 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cantourage Group SE has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Cantourage Group SE's Earnings Yield (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cantourage Group SE ranks #674 out of 1007 companies for Earnings Yield (Joel Greenblatt) %. This places Cantourage Group SE in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.25, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Cantourage Group SE and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cantourage Group SE's current Earnings Yield (Joel Greenblatt) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantourage Group SE stock overvalued right now?
Cantourage Group SE (FRA:HIGH) has a current Earnings Yield (Joel Greenblatt) % of 0.00%. The current Earnings Yield (Joel Greenblatt) % is 0.00%. Cantourage Group SE's overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Cantourage Group SE (FRA:HIGH), the current Earnings Yield (Joel Greenblatt) % is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cantourage Group SE is engaged in the manufacture and wholesale of medicinal preparations based on cannabis and the trade and distribution of other legally permissible cannabis products, medical devices, pharmaceuticals, and accessories. The group offers cannabis flowers, dronabinol, CBD, and extracts of various strains.
20GF Score
Get the complete analysis for FRA:HIGH
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HIGH has been successfully added to your 
